Increased Ketorolac Administration After Cesarean Section and Its Effect on Opioid Use: a Randomized Control Trial

Summary

To evaluate the efficacy of increased ketorolac in reducing opioid use after cesarean section.

Timeline

Start

2019-05-30

Primary completion

2022-01-31

Completion

2022-06-30

Outcome

Met primary endpoint

paper Compared with placebo, scheduled intravenous ketorolac significantly decreased opioid use after cesarean delivery. PMID 36897140 ↗

paper Hodges-Lehmann median difference -30.0, 95% CI -45.0 to -15.0, P <.001 PMID 36897140 ↗

Publications

• Hostage J, Kolettis D, Sverdlov D, Ludgin J, Drzymalski D, Sweigart B, Mhatre M, House M. Increased Scheduled Intravenous Ketorolac After Cesarean Delivery and Its Effect on Opioid Use: A Randomized Controlled Trial. Obstet Gynecol. 2023 Apr 1;141(4):783-790. doi: 10.1097/AOG.0000000000005120. Epub 2023 Mar 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ketorolac	Other / unclassified	30 mg	Intravenous

Indications